drugset / Trial / NCT06811844
Two-cycle and Three-cycle Induction Therapy With Modified TPF Regimen Combined and Camrelizumab for LANPC
RandomizedParallel-groupOpen-labelTreatment
Summary
This prospective, phase II, multicenter, randomized controlled study aims to compare the complete response rate and long-term survival outcomes of two-cycle and three-cycle induction therapy with modified TPF regimens combined with camrelizumab in patients with locally advanced nasopharyngeal carcinoma.
Timeline
- Start
- 2025-02-25
- Primary completion
- 2027-12-31
- Completion
- 2029-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Camrelizumab | Monoclonal antibody | 200 mg | Intravenous |
| Subject | Cisplatin | Other / unclassified | 25 mg/m2 | — |
| Subject | Nab-paclitaxel | Small molecule | 260 mg/m2 | — |
| Subject | Two-cycle induction chemotherapy + immunotherapy | Unknown | 40 mg | Oral |
| Subject | Two-cycle induction chemotherapy + immunotherapy | Unknown | 50 mg | Oral |
| Subject | Two-cycle induction chemotherapy + immunotherapy | Unknown | 60 mg | Oral |